77. (New) A vaccine comprising at least a portion of a CMV genome that can generate an immune response in a mammal, wherein the CMV genome or portion thereof is attenuated through inhibition of expression or activity of US28 and/or a US28 homolog.

78. (New) The vaccine of claim 77, further comprising a pharmaceutically acceptable carrier.

79. (New) The vaccine of claim 78, wherein the carrier is an adjuvant that stimulates a T-cell response in the mammal.

80. (New) The vaccine of claim 79, wherein the carrier is Freund's adjuvant or Ribi adjuvant.

81. (New) The vaccine of claim 77, wherein the mammal is a human and the CMV genome is HCMV.

B3 Cont'd.

82. (New) The vaccine of claim 81, wherein at least a segment of the HCMV genome encoding US28, UL33 and/or UL78 has been inactivated.

83. (New) The vaccine of claim 82, wherein the segment of the HCMV genome encoding US28, UL33 and/or UL78 has been deleted.

84. (New) The vaccine of claim 82, further comprising a pharmaceutically acceptable carrier.

85. (New) The vaccine of claim 84, wherein the carrier is an adjuvant that stimulates a T-cell response in humans.

86. (New) The vaccine of claim 84, wherein at least a portion of the HCMV genome encoding US28 has been inactivated.

87. (New) The vaccine of claim 86, wherein the segment of the HCMV genome encoding US28 has been deleted.

88. (New) The vaccine of claim 84, wherein at least a portion of the HCMV genome encoding human UL33 has been inactivated.

89. (New) The vaccine of claim 88, wherein the segment of the HCMV genome encoding human UL 33 has been deleted.

90. (New) The vaccine of claim 84, wherein at least a portion of the HCMV genome encoding human UL78 has been inactivated.

91. (New) The vaccine of claim 90, wherein the segment of the HCMV genome encoding human UL78 has been deleted.

92. (New) The vaccine of claim 77, wherein the mammal is rhesus monkey and the CMV genome is rhCMV.

B3

93. (New) The vaccine of claim 92, wherein at least a portion of the rhCMV genome encoding rhUS28.1, rhUS28.2, rhUS28.3, rhUS28.4, rhUS28.5, rhUL33, and/or rhUL78 has been inactivated.

94. (New) The vaccine of claim 93, wherein the segment of the rhCMV genome encoding rhUS28.1, rhUS28.2, rhUS28.3, rhUS28.4, rhUS28.5, rhUL33, and/or rhUL78 has been deleted.

95. (New) The vaccine of claim 93, further comprising a pharmaceutically acceptable carrier.

96. (New) The vaccine of claim 95, wherein the carrier is an adjuvant that stimulates a T-cell response in rhesus monkey.

97. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUS28.1 has been inactivated.

98. (New) The vaccine of claim 97, wherein the segment of the rhCMV genome encoding rhUS28.1 has been deleted.

99. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUS28.2 has been inactivated.

100. (New) The vaccine of claim 99, wherein the segment of the rhCMV genome encoding rhUS28.2 has been deleted.

101. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUS28.3 has been inactivated.

102. (New) The vaccine of claim 101, wherein the segment of the rhCMV genome encoding rhUS28.3 has been deleted.

103. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUS28.4 has been inactivated.

104. (New) The vaccine of claim 103, wherein the segment of the rhCMV genome encoding rhUS28.4 has been deleted.

105. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUS28.5 has been inactivated.

106. (New) The vaccine of claim 105, wherein the segment of the rhCMV genome encoding rhUS28.5 has been deleted.

107. (New) The vaccine of claim 95, wherein at least a portion of the rhCMV genome encoding rhUL33 has been inactivated.

108. (New) The vaccine of claim 107, wherein the segment of the rhCMV genome encoding rhUL33 has been deleted.